Narrowband UVB (NB-UVB) and the 308nm excimer laser are both well-established phototherapies in dermatology. The joint guidelines of the American Academy of Dermatology and the National Psoriasis Foundation give NB-UVB, and targeted phototherapy with the 308nm excimer laser or excimer lamp, a Grade A recommendation for localized plaque psoriasis (1). Asking which of the two is “better” is therefore the wrong question. The more useful question is which one fits a given patient and a given practice.

In a comparison of excimer laser vs narrowband UVB, four factors usually decide the outcome: how much of the skin is involved, what the treatment goal is, how many patients the clinic treats each week, and how the clinic’s staff and treatment rooms are organized. The sections below look at each technology on its own terms and then consider what this means for equipment decisions.

How Excimer Laser and Narrowband UVB Differ

Both technologies work in the UVB range and share much of their biological mechanism. UVB exposure induces apoptosis of activated T-lymphocytes in lesional skin and reduces the inflammatory activity that drives psoriasis. In vitiligo, the same wavelength range stimulates melanocytes from the hair follicle reservoir, which is why early repigmentation typically appears around follicles (2, 3).

The main difference between excimer laser and narrowband UVB lies in how the light is produced and delivered.

Narrowband UVB uses fluorescent lamps that emit in the 311–313nm band. The light is delivered through full-body cabinets or panels, so the entire skin surface, or a large region of it, is exposed during each session.

The 308nm excimer laser produces light from a xenon-chloride (XeCl) gas mixture. The beam is monochromatic and coherent and is delivered through a handpiece directly onto individual lesions (2, 3). Because surrounding skin is not irradiated, the dose applied to each plaque or patch can be considerably higher than a cabinet could safely deliver to the whole body. Laboratory data also suggest a biological difference: in one in-vitro comparison, the XeCl laser induced T-cell apoptosis at a dose roughly six times lower than NB-UVB (4).

A related device, the excimer lamp, uses the same 308nm XeCl source but emits non-coherent light, usually over a somewhat larger treatment field. Clinical results with the lamp and the laser are broadly comparable (5).

So when a 308nm excimer laser vs NB-UVB decision comes up, it is really a choice between localized and whole-body phototherapy. That distinction explains most of the practical differences described below.

Where Targeted Excimer Laser Outperforms

The excimer laser is most useful when disease is limited to a relatively small number of lesions, especially lesions that are resistant to treatment or located in anatomically difficult areas.

Localized psoriasis. The laser’s main advantage in psoriasis is efficiency. In the first published comparison, which included only six patients, clearance with the excimer laser required a cumulative dose 6.47 times lower and 3.6 times fewer treatments than NB-UVB (6). The study was small and non-randomized, but later work pointed in the same direction. In a multicenter study of 124 patients with stable plaque psoriasis covering less than 10% of body surface area, 84% achieved at least 75% improvement in target plaques after ten or fewer treatments (7). Scalp and palmoplantar plaques, which respond poorly to cabinet-based treatment, can also be treated directly with a handpiece (3, 5).

Vitiligo. Response depends heavily on anatomic site. In one body-site analysis, 50% or greater repigmentation was achieved in 74% of face and neck lesions, but in only 25% of extremity lesions. Patients whose disease had been present for two years or less responded markedly better than those with longer-standing disease (8). A randomized paired-lesion study found that localized 308nm excimer light induced repigmentation more rapidly than targeted 311nm NB-UVB (9). Targeted treatment also avoids tanning of the surrounding normal skin, which can make vitiligo patches more visible during whole-body exposure. Response improves further when the laser is combined with topical calcineurin inhibitors. A meta-analysis of randomized trials found this combination superior to laser monotherapy (10).

Other limited lesions. Alopecia areata, early-stage mycosis fungoides, granuloma annulare, and localized scleroderma have all been treated with the excimer laser (3, 5). Most of this evidence comes from case reports and small series. It supports use in selected patients, not routine first-line treatment.

Treatment schedules are similar to those used for NB-UVB. Sessions are usually given two to three times per week on non-consecutive days, and eye protection is required at every session (12). In vitiligo, repigmentation depends on the cumulative number of treatments, and about 20 sessions are generally needed before response can be judged (12).

In every one of these settings, the shared advantage is precision. The dose goes to the affected skin, uninvolved skin is spared, and the cumulative UV exposure over a course of treatment is lower. In selected patients with limited disease, the course can also be shorter.

Where Full-Body Narrowband UVB Wins

A handpiece treats one area at a time. When disease is widespread, that becomes a real limitation, and NB-UVB is the logical choice.

Widespread psoriasis. NB-UVB carries a Grade A recommendation for psoriasis, typically delivered two to three times per week (1). In a patient with dozens of plaques, a single cabinet exposure covers everything that would otherwise require a long session of lesion-by-lesion laser work.

Generalized vitiligo. In any phototherapy for vitiligo comparison, the key evidence is the 2016 meta-analysis by Lopes and colleagues. It found no statistically significant difference in 50% or 75% repigmentation between excimer devices and NB-UVB (11). Because final outcomes are similar, treatment area becomes the deciding factor. NB-UVB remains first-line for generalized vitiligo, and targeted treatment is better suited to localized disease (12). The same meta-analysis also found no significant difference in outcome between the excimer lamp and the excimer laser (11).

Other inflammatory dermatoses involving large areas. Whole-body delivery is the practical option whenever the skin to be treated extends beyond what a handpiece can cover in a reasonable session. The same general logic applies to patients whose disease is extensive or rapidly progressive (12).

Workflow and throughput. Cabinet sessions are brief and standardized, and they follow set dosing protocols. Session length does not grow with the number of lesions. For a clinic treating many patients with widespread disease, this makes NB-UVB the more efficient use of staff time and treatment rooms. Looked at the other way, narrowband UVB vs excimer laser is not a contest of clinical power but of coverage: NB-UVB treats the whole body in one exposure, while the excimer laser treats selected lesions with more precision.

Picking the Right System for Your Practice

Once the clinical indications are clear, choosing between an excimer laser or narrowband UVB becomes a question of practice management. The following points are worth working through before purchase.

Patient demographics. Look at the practice’s actual case mix. A clinic seeing mainly limited plaque psoriasis, scalp disease, facial vitiligo, or pediatric patients with a few lesions will make heavy use of a targeted device. A practice with many patients who have extensive psoriasis or generalized vitiligo will rely more on whole-body treatment.

Space. A full-body cabinet requires a dedicated room. An excimer laser is compact and can be used in a standard examination room.

Treatment volume and staff time. Cabinet treatment requires relatively little staff involvement once a protocol is set. Excimer treatment takes more hands-on time per patient, because each lesion is treated individually. In return, it can bring localized disease under control in fewer visits (6, 7).

Reimbursement. In the United States, excimer laser treatment of psoriasis is billed under dedicated CPT codes 96920–96922. Payers commonly cover it after conservative therapy has failed, and some limit the number of sessions per treatment area (13). Coverage for vitiligo varies more between payers and should be checked locally.

Patient selection. Contraindications are largely shared between the two technologies. Photosensitivity disorders, a personal history of melanoma or other skin cancer, and the use of photosensitizing medications call for caution with both targeted and whole-body treatment (12).

Long-term utilization. Equipment only pays for itself if it is used regularly. A device that suits most of the practice’s patients will be used more consistently than one chosen for a small subgroup.

For many practices, the answer is to offer both technologies rather than choose between them. Looking at the excimer laser compared to narrowband UVB in routine practice, the two turn out to cover different patients. The cabinet manages widespread disease efficiently, and the laser handles resistant plaques, difficult sites, and localized vitiligo. The same patient may move between them as the disease changes: whole-body NB-UVB during an extensive flare, followed by targeted treatment of residual plaques.

UVTreat supplies both 308nm excimer systems for targeted treatment and narrowband UVB systems for whole-body and regional phototherapy. This allows a clinic to build its phototherapy service around the patients it actually treats. In any phototherapy for psoriasis comparison, the evidence supports the same conclusion: both technologies are effective, and the right choice depends on how much skin needs treatment.

References

1. Elmets CA, Lim HW, Stoff B, et al. Joint AAD–NPF guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019;81(3):775–804. https://pubmed.ncbi.nlm.nih.gov/31351884/
2. Passeron T, Ortonne JP. Use of the 308-nm excimer laser for psoriasis and vitiligo. Clin Dermatol. 2006;24(1):33–42. https://pubmed.ncbi.nlm.nih.gov/16427504/
3. Mehraban S, Feily A. 308nm excimer laser in dermatology. J Lasers Med Sci. 2014;5(1):8–12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4290518/
4. Novák Z, Bónis B, Baltás E, et al. Xenon chloride ultraviolet B laser is more effective in treating psoriasis and in inducing T cell apoptosis than narrow-band ultraviolet B. J Photochem Photobiol B. 2002;67(1):32–38. https://pubmed.ncbi.nlm.nih.gov/?term=Xenon+chloride+ultraviolet+B+laser+is+more+effective+in+treating+psoriasis
5. Hartmann Schatloff D, Retamal Altbir C, Valenzuela F. The role of excimer light in dermatology: a review. An Bras Dermatol. 2024;99(6):887–894. https://www.sciencedirect.com/science/article/pii/S0365059624001612
6. Bónis B, Kemény L, Dobozy A, et al. 308 nm UVB excimer laser for psoriasis. Lancet. 1997;350(9090):1522. https://pubmed.ncbi.nlm.nih.gov/?term=Bonis+308+nm+UVB+excimer+laser+for+psoriasis+Lancet+1997
7. Feldman SR, Mellen BG, Housman TS, et al. Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad Dermatol. 2002;46(6):900–906. https://pubmed.ncbi.nlm.nih.gov/?term=Efficacy+of+the+308-nm+excimer+laser+for+treatment+of+psoriasis+multicenter+study
8. Hofer A, Hassan AS, Legat FJ, Kerl H, Wolf P. The efficacy of excimer laser (308 nm) for vitiligo at different body sites. J Eur Acad Dermatol Venereol. 2006;20(5):558–564. https://pubmed.ncbi.nlm.nih.gov/16684284/
9. Poolsuwan P, Churee C, Pattamadilok B. Comparative efficacy between localized 308-nm excimer light and targeted 311-nm narrowband ultraviolet B phototherapy in vitiligo: a randomized, single-blind comparison study. Photodermatol Photoimmunol Photomed. 2021;37(2):123–130. https://pubmed.ncbi.nlm.nih.gov/?term=Poolsuwan+308-nm+excimer+light+311-nm+narrowband+vitiligo
10. Bae JM, Eun SH, Lee HN, et al. The efficacy of 308-nm excimer laser/light (EL) and topical agent combination therapy versus EL monotherapy for vitiligo: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2016;74(5):907–915. https://pubmed.ncbi.nlm.nih.gov/?term=Bae+308-nm+excimer+laser+topical+agent+combination+vitiligo+meta-analysis
11. Lopes C, Trevisani VFM, Melnik T. Efficacy and safety of 308-nm monochromatic excimer lamp versus other phototherapy devices for vitiligo: a systematic review with meta-analysis. Am J Clin Dermatol. 2016;17(1):23–32. https://pubmed.ncbi.nlm.nih.gov/26520641/
12. DermNet NZ. Excimer 308-nm light treatment. https://dermnetnz.org/topics/excimer-308-nm-light-treatment
13. Laser treatment for psoriasis (medical policy). https://www.healthplan.org/application/files/7916/8124/6558/Laser_Treatment_for_Psoriasis.pdf

Stay updated, free articles. Join our Telegram channel

Join